Lupisit M 50mg/500mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these agents helps achieve better glycemic regulation than monotherapy. Lupisit M is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either component alone or those already receiving combination therapy. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of renal function and blood glucose levels is recommended during therapy to minimize risks and optimize treatment outcomes.